Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™

First once-daily dosing results for the HIV protease inhibitor Agenerase ™:
Clinical Importance: Development of once-daily HIV regimens represents a major advance toward simplified therapy for patients.
First phase II clinical results for amprenavir prodrug (VX-175):
VX-175 could provide significant simplification of protease inhibitor-based therapy by potentially allowing dosing of just two or three pills, once or twice a day.
Meet with a Vertex medical director or clinical investigator to learn about advancements in Vertex’s HIV product pipeline.
Learn how pharmacokinetic discoveries are enhancing dosage convenience and promoting patient adherence to therapy

February 4-8, 2001
Sheraton Hotel and Towers, Chicago, IL
Visit us at Posters #332 and 333 (Feb 6th)

###

For more information Contact:
Renee Connolly of Noonan/Russo Communications, Inc., 212-696-4455 ext 227,
r.connolly@noonanrusso.com
or
Michael Partridge of Vertex Pharmaceuticals, Incorporated, 617-577-6108
michael_partridge@vpharm.com

[ | E-mail |

Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.